File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and safety of anti-obesity drugs in children and adolescents: Systematic review and meta-analysis: Obesity management

TitleEfficacy and safety of anti-obesity drugs in children and adolescents: Systematic review and meta-analysis: Obesity management
Authors
Issue Date2010
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/OBR
Citation
Obesity Reviews, 2010, v. 11 n. 8, p. 593-602 How to Cite?
AbstractWe undertook a meta-analysis of randomized controlled trials to summarize the efficacy of anti-obesity drugs in reducing BMI and improving health in children and adolescents. Data sources included Medline, Embase, the Cochrane controlled trials register and other registers of controlled trials, together with reference lists of identified articles. All data sources were searched from January 1996 to July 2008. We searched for double blind randomized placebo controlled trials of approved anti-obesity drugs used in children and adolescents (age <20) with primary obesity for ≥6 months. Six trials, 4 of sibutramine (total patients = 686) and 2 of orlistat (n = 573) met inclusion criteria. No trials of rimonabant were identified. Compared with placebo, sibutramine together with behavioural support reduced BMI by 2.20 kg/m 2 (95% CI: 1.57 to 2.83) and orlistat together with behavioural support reduced BMI by 0.83 kg/m 2 (95% CI 0.47 to 1.19). Sibutramine improved waist circumference, triglycerides and high density lipoprotein (HDL)-cholesterol, but raised systolic and diastolic blood pressure and pulse. Orlistat increased rates of gastrointestinal side-effects. We conclude that sibutramine in adolescents produces clinically meaningful reductions in BMI and waist circumference of approximately 0.63 SD, with improvements in cardiometabolic risk. Orlistat modestly reduces BMI (effect size approximately 0.24 SD) with a high prevalence of gastrointestinal adverse effects. © 2009 International Association for the Study of Obesity.
Persistent Identifierhttp://hdl.handle.net/10722/171404
ISSN
2015 Impact Factor: 7.51
2015 SCImago Journal Rankings: 4.277
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorViner, RMen_US
dc.contributor.authorHsia, Yen_US
dc.contributor.authorTomsic, Ten_US
dc.contributor.authorWong, ICKen_US
dc.date.accessioned2012-10-30T06:13:56Z-
dc.date.available2012-10-30T06:13:56Z-
dc.date.issued2010en_US
dc.identifier.citationObesity Reviews, 2010, v. 11 n. 8, p. 593-602en_US
dc.identifier.issn1467-7881en_US
dc.identifier.urihttp://hdl.handle.net/10722/171404-
dc.description.abstractWe undertook a meta-analysis of randomized controlled trials to summarize the efficacy of anti-obesity drugs in reducing BMI and improving health in children and adolescents. Data sources included Medline, Embase, the Cochrane controlled trials register and other registers of controlled trials, together with reference lists of identified articles. All data sources were searched from January 1996 to July 2008. We searched for double blind randomized placebo controlled trials of approved anti-obesity drugs used in children and adolescents (age <20) with primary obesity for ≥6 months. Six trials, 4 of sibutramine (total patients = 686) and 2 of orlistat (n = 573) met inclusion criteria. No trials of rimonabant were identified. Compared with placebo, sibutramine together with behavioural support reduced BMI by 2.20 kg/m 2 (95% CI: 1.57 to 2.83) and orlistat together with behavioural support reduced BMI by 0.83 kg/m 2 (95% CI 0.47 to 1.19). Sibutramine improved waist circumference, triglycerides and high density lipoprotein (HDL)-cholesterol, but raised systolic and diastolic blood pressure and pulse. Orlistat increased rates of gastrointestinal side-effects. We conclude that sibutramine in adolescents produces clinically meaningful reductions in BMI and waist circumference of approximately 0.63 SD, with improvements in cardiometabolic risk. Orlistat modestly reduces BMI (effect size approximately 0.24 SD) with a high prevalence of gastrointestinal adverse effects. © 2009 International Association for the Study of Obesity.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/OBRen_US
dc.relation.ispartofObesity Reviewsen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAnti-Obesity Agents - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAppetite Depressants - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBody Mass Indexen_US
dc.subject.meshChilden_US
dc.subject.meshCognitive Therapyen_US
dc.subject.meshCombined Modality Therapyen_US
dc.subject.meshConsumer Product Safetyen_US
dc.subject.meshCyclobutanes - Adverse Effects - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLactones - Adverse Effects - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshObesity - Drug Therapyen_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshWaist Circumference - Drug Effectsen_US
dc.subject.meshWeight Lossen_US
dc.titleEfficacy and safety of anti-obesity drugs in children and adolescents: Systematic review and meta-analysis: Obesity managementen_US
dc.typeArticleen_US
dc.identifier.emailWong, ICK:wongick@hku.hken_US
dc.identifier.authorityWong, ICK=rp01480en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1467-789X.2009.00651.xen_US
dc.identifier.pmid19922432-
dc.identifier.scopuseid_2-s2.0-77954748599en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77954748599&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume11en_US
dc.identifier.issue8en_US
dc.identifier.spage593en_US
dc.identifier.epage602en_US
dc.identifier.isiWOS:000280968900005-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridViner, RM=7005899067en_US
dc.identifier.scopusauthoridHsia, Y=35068032100en_US
dc.identifier.scopusauthoridTomsic, T=36553535400en_US
dc.identifier.scopusauthoridWong, ICK=7102513915en_US
dc.identifier.citeulike7601065-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats